T-Cell and Other Lymphoproliferative Malignancies (C Dearden, Section Editor)

Current Hematologic Malignancy Reports

, Volume 7, Issue 4, pp 285-291

First online:

Targeting CD30 in Anaplastic Large Cell Lymphoma

  • Joseph VadakaraAffiliated withFox Chase Cancer Center
  • , Barbara ProAffiliated withFox Chase Cancer Center Email author 

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access


Anaplastic large cell lymphoma (ALCL) is a lymphoid neoplasm characterized by strong and uniform expression of the CD30 antigen on the cell surface. Current standard frontline therapy of ALCL is anthracycline-based combination chemotherapy, usually CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone) or CHOP-like regimens. Despite aggressive chemotherapy a significant number of patients relapse. Newer agents and strategies are needed in the management of this challenging disease especially in ALK-negative and high-risk ALK-positive patients who tend to have a poor prognosis. In this review we discuss the different approaches to targeting CD30 including naked antibodies, “enhanced antibodies”, antibody drug–toxin conjugates, radioimmunoconjugates, CD30-ligand–toxin conjugates, bispecific antibodies and T cell-based immune therapies.


Anaplastic large cell lymphoma CD30 SGN-35 Brentuximab Vedotin MMAE T-cell lymphoma